Abstract
We evaluated the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) against cefepime-resistant Acinetobacter baumannii strains (n = 13) in the neutropenic murine lung infection model. Twelve isolates were meropenem resistant. In control animals and those that received cefepime or zidebactam alone, the mean bacterial growth at 24 h was >2 log10 CFU/lung compared with 0-h controls (6.32 ± 0.33 log10 CFU/lung). WCK 5222 produced a decline in the bacterial burden for all isolates (mean reduction, -3.34 ± 0.85 log10 CFU/lung) and demonstrated remarkable potency.
Keywords:
Acinetobacter; carbapenem resistant; lung infection.
Copyright © 2018 American Society for Microbiology.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acinetobacter baumannii / drug effects*
-
Animals
-
Anti-Bacterial Agents / pharmacology*
-
Azabicyclo Compounds / pharmacology*
-
Carbapenems / pharmacology*
-
Cefepime / pharmacology*
-
Cephalosporins / pharmacology*
-
Cyclooctanes / pharmacology*
-
Drug Resistance, Multiple, Bacterial / drug effects*
-
Female
-
Lung / microbiology
-
Lung Diseases / drug therapy*
-
Lung Diseases / microbiology
-
Mice
-
Mice, Inbred ICR
-
Microbial Sensitivity Tests / methods
-
Piperidines / pharmacology*
-
beta-Lactamase Inhibitors / pharmacology
Substances
-
Anti-Bacterial Agents
-
Azabicyclo Compounds
-
Carbapenems
-
Cephalosporins
-
Cyclooctanes
-
Piperidines
-
WCK 5222
-
beta-Lactamase Inhibitors
-
zidebactam
-
Cefepime